FGF22-IN-1

CAS No. 113143-13-8

FGF22-IN-1( —— )

Catalog No. M36498 CAS No. 113143-13-8

FGF22-IN-1 is a potential CD4 N-terminal immunoglobulin variable region-like domain (CD4 D1) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 68 Get Quote
5MG 101 Get Quote
10MG 163 Get Quote
25MG 302 Get Quote
50MG 495 Get Quote
100MG 689 Get Quote
500MG 1395 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    FGF22-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    FGF22-IN-1 is a potential CD4 N-terminal immunoglobulin variable region-like domain (CD4 D1) inhibitor.
  • Description
    FGF22-IN-1 (compound c1) is a potent CD4 D1 inhibitor. FGF22-IN-1 can be used as immunosuppressive agent.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    113143-13-8
  • Formula Weight
    269.32
  • Molecular Formula
    C14H11N3OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (371.31 mM; Ultrasonic )
  • SMILES
    O=C(NN=CC1=CNC=2C=CC=CC12)C=3SC=CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Xiao H, et al. Potent inhibition of the CD4-dependent T cell response by J2, a novel nonpeptide organic ligand of CD4 D1. Mol Immunol. 2007 Feb;44(5):784-95.?
molnova catalog
related products
  • 6-O-Galloylglucose

    The leaves of Camellia sinensis.

  • MAO-B-IN-5

    MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) .

  • Graveobioside A

    Graveobioside A can be used in hyperuricemia and gout-resistant drugs or health foods.